Lumida
/PBYI
⌘K
Puma Biotechnology Inc

Puma Biotechnology Inc

PBYI
$9.12USD-0.55%-0.05 today

MARKET CAP

470.8M

P/E (TTM)

17.6x

FWD P/E

22.0x

DAY RANGE

$9 – $9

52W RANGE

$4
$10

AI Summary

Stalk
Sell NowMedium

The asset exhibits a classic blow-off top with a long upper wick and high-volume exhaustion in Stage 2, suggesting medium-term reversal risk; short-term rejection at resistance and overbought conditions favor immediate bearish engagement through a sell now posture, targeting the recent resistance zone with rejection-based execution.

  • Q2 total revenue $56.5M (up from $49.2M YoY); NERLYNX product sales +27% QoQ.
  • 2026 revenue guidance raised to $205–209M, reflecting strong market demand.
  • NERLYNX drives majority of sales, posing single‐product concentration risk.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$253.2M$228.0M$235.6M$230.5M$228.4M
YoY %+12.5%-9.9%+3.3%-2.2%-0.9%
P / Sales0.5x0.8x0.9x0.6x1.3x
EV / Sales1.1x1.4x1.3x0.9x1.6x
Gross Profit, Adj.$189.5M$172.9M$173.0M$166.1M$170.2M
YoY %+2.0%-8.7%+0.0%-4.0%+2.5%
Margin %74.8%75.8%73.4%72.1%74.5%
EV / Gross Profit1.5x1.8x1.8x1.2x2.1x
EBITDA, Adj.$12.6M$33.6M$44.2M$42.5M$48.2M
YoY %+161.8%+166.5%+31.6%-3.8%+13.5%
Margin %5.0%14.7%18.7%18.4%21.1%
EV / EBITDA23.0x9.2x7.0x4.7x7.4x
EBIT$1.3M$11.3M$32.6M$31.0M$37.3M
YoY %+104.2%+773.2%+189.8%-5.1%+20.5%
Margin %0.5%4.9%13.9%13.4%16.3%
EV / EBIT224.4x27.5x9.4x6.5x9.6x
Net Income$-29.1M$2,000$21.6M$30.3M$31.1M
YoY %+51.5%+100.0%+1079450.0%+40.2%+2.8%
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (GAAP)-$0.72$0.45$0.62$0.61
YoY %+52.6%+37.8%-1.6%